Last reviewed 2026-04-20 · How we verify

Alpha-1 MP

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Hyperglycaemia
• Oedema peripheral
• Hypomagnesaemia
• Hypoalbuminaemia
• Abdominal pain
• Hypertension
• Hypophosphataemia
• Hypocalcaemia
• Alanine aminotransferase increased
• Dry mouth
• Hyperkalaemia
• Hyponatraemia

Key clinical trials

• Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) (PHASE3)
• Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency (PHASE3)
• Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) (PHASE1, PHASE2)
• Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency (PHASE1, PHASE2)
• Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (PHASE2)
• Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults (PHASE3)
• The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency (PHASE3)
• Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Alpha-1 MP CI brief — competitive landscape report
• Alpha-1 MP updates RSS · CI watch RSS
• Grifols Therapeutics LLC portfolio CI